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Characterizing the putative G1/S transcription factor complex composition and function in 
Candida albicans 
Vinitha Joice Chidipi 
 
The G1/S transition is a critical control point for cell proliferation, and involves the 
essential transcription complexes SBF and MBF in Saccharomyces cerevisiae, or MBF in 
Schizosaccharomyces pombe. In S. cerevisiae, Swi4p and Mbp1p comprise the DNA binding 
elements for SBF and MBF, respectively, while Swi6p is a common activating component. In the 
fungal pathogen Candida albicans, G1/S regulation is not yet clear. Orthologues of Swi6p, 
Swi4p and Mbp1p exist and previous work suggested that Swi4p and Swi6p form a single G1/S 
transcription factor complex, while the function of Mbp1p remained unclear as its absence did 
not affect growth. Additionally, unknown factors were suggested to contribute to G1/S regulation 
in C. albicans as cells lacking Swi4p and Swi6p, or Swi4p and Mbp1p were still viable, unlike 
the situation in S. cerevisiae. A previous graduate student from the Bachewich lab demonstrated 
through tandem-affinity purification of Swi4p, Swi6p and Mbp1p coupled with Orbitrap LC/MS, 
and co-immunoprecipitation that Swi6p interacted with Swi4p as well as Mbp1p, but an 
interaction between Swi4p and Mbp1p was not clear, questioning the current model that Swi4p 
and Swi6p are the major components of a single MBF-like complex in C. albicans. Additional 
putative interacting proteins were identified but not validated. Further, identification of Swi4p 
targets using genome-wide location analysis revealed cell-cycle related factors but also 
regulators of filamentous growth, including EFG1. In this study, the composition of the putative 
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G1/S transcription factor complex was further investigated using co-immunoprecipitation 
experiments that utilized lower amounts of input protein and variations in epitope tags. The 
results confirm that Swi6p similarly interacts with Swi4p and Mbp1p. However, Swi4p and 
Mbp1p showed a weak interaction that could only be detected with higher amounts of input 
protein and only when Swi4p was immune-precipitated. Thus, separate Swi6p/Swi4p and 
Swi6/Mbp1p complexes may exist in C. albicans, but the function of the Swi6p/Mbp1p complex 
remains unknown. We next carried out co-immunoprecipiation experiments to validate 
additional proteins identified in the previous Swi6p affinity purification screen, including the 
mitotic polo-like kinase Cdc5p. When Cdc5p was immune-precipitated from G1-phase arrested 
cells, Swi6p co-purified, suggesting a novel interaction between these two proteins. Finally, in 
order to validate the functional significance of Swi4p occupation of the EFG1 promoter, EFG1 
expression in the presence and absence of Swi4p was investigated by Northern blotting, and the 
effects of deleting EFG1 on the Swi4p-depleted phenotype were determined. In the absence of 
Swi4p, EFG1 was moderately induced. Furthermore, absence of EFG1 reduced the extent to 
which swi4/swi4 cells became enlarged and formed long filaments. Thus, Swi4p may 
contribute to the regulation of EFG1 and possibly filamentous morphogenesis, as well as the 
G1/S transition, suggesting that it may lie at the interface between cell cycle regulation and 
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1.1 Eukaryotic Cell Cycle 
1.1.1 General Overview    
 
The cell cycle is a series of events that lead to duplication of DNA and creation of two 
new daughter cells. In many organisms, it consists of G1, S, G2, M phases and cytokinesis. Cell 
growth and DNA replication occur in G1 and S phase, respectively. The cell continues to grow in 
G2. In M phase, the duplicated DNA aligns on a spindle and then is segregated to two daughter 
cells. The cells divide during cytokinesis [1].  
Progression through the cell cycle is controlled at many levels, and several checkpoints, 
to ensure that processes in each phase are successfully completed before proceeding into the next 
phase. The cyclin-dependent kinases (Cdks) associated with specific cyclins are major regulators 
of cell cycle transitions. For example, in the model yeast Saccharomyces cerevisiae, the G1 
cyclins Cln1 – Cln3 bind to Cdk Cdc28p to regulate the G1/S transition. However, Cdc28p 
associates with B-type cyclins to regulate the transition from G2 phase into mitosis [2].  
Proper cell cycle progression is crucial for cell viability and proliferation. Defects in 
genes encoding regulatory proteins that control cell cycle events can lead to uncontrolled cell 
division, eventually giving rise to many diseases such as cancer. For example, in humans, 
mutations that lead to overexpression of CDK1 and CDK2 can be a cause for certain types of 
colon adenomas as well as for focal carcinomas in adenomatous tissue [3]. Increased 
amplification of cyclin D gene can lead to breast, esophageal, bladder, lung, and squamous cell 
carcinomas [4].  
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1.1.2 G1/S transition 
 
 G1 is a crucial stage of cell cycle as it determines whether cells commit to mitosis and 
proliferate or exit the cell cycle for differentiation [5, 6]. The G1/S transition is known as the 
Restriction point in higher organisms such as mammals, or Start in lower organisms such as 
fungi. The circuitry controlling this cell cycle stage shows some conservation from yeast to 
humans. An upstream Cdk associated with cyclins is required to activate a downstream G1/S 
transcription factor complex (Fig. 1A). This complex, in turn, regulates a battery of genes 
required for cell cycle entry, including DNA replication [7]. In mammals, Cdk4 associates with 
cyclin D, and this complex activates a family of G1/S transcription factors E2F1-E2F3 [8], by 
phosphorylating and inactivating their inhibitor, Retinoblastoma protein (pRb). Targets of E2F 
include cyclins E and A, for example, which then associate with Cdk2 to further phosphorylate 
pRb forming a positive feedback loop [9]. Activated E2F initiates transcription of additional 
genes involved in DNA synthesis, chromosome replication as well as genes related to cell cycle 
regulation [8], DNA damage repair, apoptosis, differentiation and development [10]. In late S 
phase, cyclin A/Cdk2 complex phosphorylates E2F1 to inhibit its DNA binding capacity, thereby 
leading to its inactivation [11]. 
In fungi, the G1/S transition has only been well characterized in the model yeasts 
Saccharomyces cerevisiae and Schizosaccharomyces pombe. In S. cerevisiae, Start requires that 
cells have obtained a critical cell size and protein synthesis rate [12]. In S. cerevisiae, the Cdk 
Cdc28p associates with the G1 cyclin Cln3p. This complex phosphorylates and inhibits Whi5p, 
an inhibitor of one G1/S transcription complex, which is called SBF [13, 14]. A second G1/S 
transcription complex, called MBF, is activated by inhibition of the co-repressor Nrm1p [15]. 
SBF is composed of a transcriptional activator Swi6p and a DNA binding factor Swi4p, which 
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binds to SCB (CGCGAAA) elements [16] on target promoters of genes. It activates transcription 
of G1 cyclin genes, CLN1 and CLN2, for example, which in turn stimulate the activity of 
Cdc28p. This allows for a positive feedback loop, as well as transcription of B-type cyclin genes, 
CLB5 and CLB6, by inactivating their inhibitor, Sic1p via phosphorylation. The B-type cyclins 
with their associated Cdk activate S-phase targets to initiate DNA synthesis as well as spindle 
maturation and chromosome segregation [13]. MBF consists of Swi6p and a DNA binding factor 
Mbp1p that binds to MCB (CGCGT) elements [16] in genes linked to DNA synthesis and 
metabolism. Unlike SBF, MBF is involved in repressing transcription of genes outside of G1. It 
is later inactivated by Nrm1p, which accumulates in S phase and binds to MBF [16]. On the 
other hand, SBF activity is inhibited by Clb1/2p-Cdk1p complex, which accumulates during the 
G1-S transition to phosphorylate SBF, thereby causing its dissociation from promoter regions of 
target genes [16] (Fig. 1B).  
In the fission yeast model S. pombe, the cyclin Pas1p associates with the Cdk Pef1p to 
activate a single MBF complex that regulates the G1/S transition. This complex consists of the 
activating factor Cdc10p, a homologue of Swi6p, and two DNA binding elements, Res1p and 
Res2p, homologues of Mbp1p, that recognize MCB elements in genes involved in DNA 
synthesis, DNA repair and cell cycle control [17]. Res1p and Res2p bind to DNA through their N 
termini and to Cdc10p through their C termini. In contrast to S. cerevisiae, Res1p and Res2p 
together are not equally important in G1/S transition specifically. Although Res1p/Cdc10p 
complex is crucial in G1 to S progression, Res2p is additionally involved in meiosis where it 
forms a complex with Cdc10p only without the presence of Res1p. Hence, Res2p plays an 
important role in both mitotic as well as meiotic stages of cell cycle [18]. MBF activity is 
inactivated outside of G1 by transcriptional repressors Nrm1p and Yox1p, which accumulate in S 
 4 
 
phase and bind to MBF. On the other hand, it is kept activated through a stress-induced 
mechanism, in which protein kinase Cds1p phosphorylates Nrm1p, Yox1p, Cdc10p, as well as 






Figure 1. G1/S phase of cell cycle.  
(A) Activation of G1/S transition in human and yeast. (B) The components of G1/S transcription 







1.2 Candida albicans 
1.2.1 Opportunistic fungal pathogen in humans 
 
Candida albicans is a commensal fungus that resides in the gastrointestinal tract and 
mucosal membranes of humans [20, 21]. Although harmless under most circumstances, C. 
albicans is an opportunistic pathogen. It can cause mucosal infections or more life-threatening 
systemic infections in immunocompromised individuals [21]. For example, patients with AIDS 
are susceptible to oral and oesophageal candidiasis. Moreover, 75% of women are affected by 
vulvovaginal candidiasis, one of the frequently occurring infections [22]. Candidaemia, a 
bloodstream infection caused by C. albicans, is capable of spreading to internal organs such as 
brain, heart, and kidney [23]. Common drugs to address candidiasis include fungistatic drugs, 
such as fluconazole and other azoles, which inhibit the biosynthesis of fungal cell membrane 
components such as ergosterol. Other drugs are fungicidal, including the echinocandins, which 
cause cell death through the inhibition of β-1,3-glucan synthase, an enzyme required for cell wall 
biosynthesis. However, due to severe side effects and increased resistance to these drugs [24], 
new drug targets and strategies for treating infection are required. To this end, a comprehensive 
understanding of the biology of C. albicans and its virulence traits is crucial. 
1.2.2 Virulence-associated traits: Differentiation 
 
One aspect of the biology of C. albicans that is essential for virulence is its ability to 
differentiate into multiple cell types, including yeast, pseudohyphae, hyphae, and 
chlamydospores [21]. Yeast cells are oval and separate after cytokinesis. Pseudohyphae are 
elongated yeast due to an extended period of polarized growth, but remain attached after cell 
division and thus have constrictions at the sites of septation. Hyphae consist of elongated cells 
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that maintain growth in a polarized manner, and do not contain constrictions at septation sites. 
Chlamydospores have thicker cell walls and are larger compared to yeast cells [20]. Plasticity in 
form allows the fungus to survive and adapt to the different environments of the host. For 
example, yeast cells are more adept to dissemination in the blood stream, while the filamentous 
cells are optimized for penetrating host tissues during infection [25]. Hyphae generate physical 
forces and secrete lytic enzymes such as aspartic proteases, that aide in disintegration of cell 
surface components and contribute to entry into host cells [26].  Mutants locked in one cell form, 
including yeast or hyphae, are significantly less virulent in mouse models of infection, 
underscoring the importance of differentiation in virulence potential. An understanding of the 
factors that regulate differentiation may thus identify effective targets for anti-fungal therapies.  
Differentiation is triggered by various environmental cues. The regulation of 
differentiation is one of the best understood with respect to the yeast-to-hyphae switch. The yeast 
to hyphal transition is induced by several stimuli such as serum, high pH, nutrient limitation, and 
high CO2 concentrations under the condition of high temperature, or under embedded conditions 
[21]. Several signaling pathways are activated by stimuli, including a mitogen-activated protein 
kinase (MAPK) pathway involving the Cph1p transcription factor as well as a cyclic AMP-
dependent pathway involving the Efg1p transcription factor [21] (Fig. 2), for example.  Efg1p is 
acted upon by additional pathways and is required for hyphal development under most hyphal-
inducing conditions [27]. Efg1p in turn acts on expression of various Hyphal Specific Genes 
(HSGs), including HWP1, a cell wall protein involved in adhesion to host tissue [28] for 
example. In addition to Efg1p, Ume6p is another important transcription factor that regulates 
hyphal growth. UME6 is activated in part by Efg1p [29]. A target of Ume6p is HGC1, a hyphal-
specific gene crucial for development of hyphae [30, 31]. Hgc1p forms a complex with Cdc28p 
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to contribute to hyphal growth through various mechanisms [32]. For example, the 
Cdc28p/Hgc1p complex phosphorylates Rga2p, which is a GTPase-activating protein (GAP) of 
the polarity regulator Cdc42p [33], which in turn maintains active Cdc42p at the hyphal tip [33, 
34]. Importantly, Cdc28p/Hgc1p also phosphorylates Efg1p, which causes it to associate with 
and repress genes involved in cell separation [35]. 
Furthermore, Efg1p functions with five other important transcriptional regulators 
including Bcr1p, Tec1p, Ndt80p, Rob1p and Brg1p to regulate biofilm formation, which is 
crucial for virulence [36]. Other additional functions controlled by Efg1p include white cell-
specific transcriptional profile [37, 38], regulation of oxidative/fermentative metabolism [39], 










1.2.3 Virulence associated traits: Cell proliferation 
 
Another aspect of the biology of C. albicans that is important for virulence and survival 
in host organisms is cell proliferation, which is regulated by the cell cycle. In contrast to S. 
cerevisiae and S. pombe, the circuitry controlling the cell cycle in C. albicans is not well defined, 
due in part to the diploid nature of the fungus [41], difficulty in synchronizing cells [42], and an 
emerging theme of differences in function of the few sequence homologues that have been 
characterized in C. albicans [43]. However, one study demonstrated the ability to synchronize 
the opaque yeast form of C. albicans [42], and through this identified genes that are modulated at 
the transcriptional level during G1/S, S/G2, G2/M, and M/G1 transitions. This work revealed 
some similarity to S. cerevisiae, but also identified many novel genes whose expression was 
modulated at G1/S and other cell cycle transitions. However, few have been functionally 
characterized. Of the G1/S modulated genes, there was a significant enrichment of MCB motifs 
in promoter regions, but not SCB, unlike that found with G1/S-modulated genes in S. cerevisiae 
[42]. Hence, a model was proposed whereby a single MBF complex that binds MCB elements 
might control genes at the G1/S transition in C. albicans, more similar to the situation in S. 
pombe.  
Sequence comparisons and limited genetic studies demonstrated that C. albicans shares 
some similarity in the putative G1/S regulatory circuit with S. cerevisiae. For example, C. 
albicans contains orthologues of Cdc28p, the G1 cyclin, Cln3p and the G1/S transcription 
complex factors Swi6p, Swi4p and Mbp1p. Repression of Cdc28p caused cell elongation as well 
as changes in expression of hyphal-associated genes and transcription factors related to 
morphogenesis [44]. Depletion of the G1 cyclin Cln3p in yeast cells resulted in large, unbudded 
cells with a single nucleus, implying a role in G1 phase [45, 46]. However, in contrast to Cln3p-
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depleted S. cerevisiae cells, which eventually resume budding due to the presence of Bck2p [47], 
which C. albicans lacks, Cln3p-depleted C. albicans cells switched to hyphal and pseudohyphal 
growth, in the absence of environmental cues [45, 46]. This suggested a link between G1 phase 
and hyphal development. C. albicans also contains orthologues of SWI4, SWI6 and MBP1. 
Deletion of SWI4 or SWI6, but not MBP1, resulted in yeast cell enlargement, suggesting a G1 
phase delay, and production of filaments [48]. However, in contrast to the situation in S. 
cerevisiae, absence of both SWI6 and SWI4 or SWI4 and MBP1, resulted in viable cells. This 
suggests that additional factors contribute to the regulation of the G1/S transition. Furthermore, 
cells lacking Swi6p/Swi4p also showed changes in expression in G1/S-associated genes 
including G1 cyclins CCN1 and PCL2, linking their function to G1/S control. Together, these 
results support the model that Swi4p and Swi6p might be key players in a single G1/S 
transcription factor complex, and thus may be the functional equivalent of MBF. A novel gene 
proposed to be the Nrm1p functional homologue was identified, but it does not appear to be 
identical [49]. Other factors required for the G1/S transition in S. cerevisiae, including Whi5p 
and Bck2p, are missing in C. albicans. In summary, C. albicans appears to have a similar 
framework for the G1/S transition network as seen in S. cerevisiae (Fig. 3), but a number of 
differences exist, including the role of Mbp1p and identity of additional contributing factors. 
Further, biochemical data supporting complex composition and a direct demonstration of 



















Figure 3. The putative components of G1/S transition pathway in C.albicans compared to 
S.cerevisiae (B.Hussein, MSc thesis, 2011). 
In order to further address these questions, a previous graduate student in the Bachewich 
lab carried out a systematic affinity purification of Swi4p, Swi6p and Mbp1p (Yaolin Chen, MSc 
thesis). Results indicated that Swi6p was the predominant binding factor of Swi4p but also for 
Mbp1p. Interestingly, affinity purification of Swi4p did not reveal enriched peptides 
corresponding to Mbp1p, nor did Swi4p co-purify with affinity-purified Mbp1p. This suggested 
that there may be two separate complexes in C. albicans, which contrasts the current model that 
suggests C. albicans contains a single complex composed of Swi4p and Swi6p. However, 
subsequent co-immunoprecipitation (Co-IP) experiments with strains carrying Mbp1p-TAP and 
Swi4p-HA, or Swi4p-5MYC and Mbp1p-HA revealed an interaction in the former but not the 
latter. Thus, the ability of Swi4p and Mbp1p to interact, and the composition and number of the 
of G1/S transcription complex(es) in C. albicans remain unclear.  
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Further, data from the affinity purification assays revealed additional factors that bind 
Swi4p and Swi6p that were not previously identified in other systems. For example, a novel 
interacting factor of Swi6p was determined to be Cdc5p, a polo-kinase involved in mitotic 
spindle formation and morphogenesis [50]. Furthermore, additional Swi4p interacting factors 
included a group of regulatory subunits associated with 26S proteasome such as Rpn1p, Rpt6p, 
and Pr26p. These proteins do not show a physical interaction with Swi4p in S. cerevisiae. The 
findings have important implications for the potential regulation of Swi4p in C. albicans.  
In order to determine the binding sequence of Swi4p and identity specific targets, Y. 
Chen also performed a genome-wide location analysis with a tiling array (ChIP-chip). Results 
showed enriched Swi4p binding at promoter regions of G1 cyclins such as CCN1 and PCL2 as 
well as G1, S phase cell cycle regulatory factors like YOX1, HSL1 and RAD53. Intriguingly, 
genes associated with filamentous growth were also identified, including important regulators of 
hyphal growth, such as Efg1p. Given that arresting cells in G1 phase can induce hyphal growth, 
and cells depleted of Swi4p or Swi6p form filaments, this promoter occupation may reflect a 
mechanism by which the G1/S machinery could be linked to the hyphal development program. 
In contrast to the enrichment for MCB elements within G1/S-associated genes indicated by the 
transcriptional analysis of cell cycle-associated genes in C. albicans [42], the Swi4p targets were 
not enriched for the MCB motif. Rather, a motif related to SBF and similar to the binding site for 
the transcription factor Ndt80p was identified. However, the analysis was based on a single tiling 
array.   
1.3 Summary 
A proper understanding of the G1/S transition in C. albicans is important in order to gain 
more insight about how cell proliferation is regulated and to further identify the specific 
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mechanisms that link this particular transition stage to hyphal development. Cell proliferation, 
and differentiation are crucial for virulence of C.albicans. Ultimately, potential drug targets 
could be identified in order to control the development of life-threatening infections in humans. 
However, the organization of G1/S transcription factor complex is not entirely clear. Additional 
components that may contribute to the regulation and/or function of this complex remain 




The objectives of this study include: 1) characterizing the composition of G1/S 
transcription factor complex by determining whether Swi4p and Mbp1p interact and validating 
additional interactors of Swi4p and Swi6p identified in the previous affinity purification system 
study; and 2) validating an important target of Swi4p identified by ChIP-chip, including Efg1p in 









2. Materials and Methods 
 
2.1 Strains, oligonucleotides and plasmids  
Strains, oligonucleotides and plasmids used in this study are shown in Tables 1, 2, and 3 
respectively.   
Table 1. Candida albicans strains used in this study 
Strain Genotype  Parent/Source 
AH110 SWI4-3HA-HIS1/SWI4, Δswi6::URA3/SWI6-TAP-ARG4 C.Bachewich 
AM201.5 Δswi6::URA3/SWI6-TAP-ARG4 C.Bachewich 
BH114 Δswi4::hisG/SWI4 [48] 
YC396 MBP1-TAP-ARG4/MBP1, Δswi6::HIS1/SWI6-3HA-URA3 YC216 
YC367 Δmbp1::HIS1/MBP1-TAP-URA3 RM100 
YC216 Δswi6::HIS1/ SWI6-HA-URA3 BH101 
YC221 SWI6-TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4 BH253 
VC132 MBP1-3HA-HIS1/MBP1, SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4 
YC221 
YC351 MBP1-HA-URA3/mbp1::HIS1  BH137 
YC101 SWI4-HA-HIS1/SWI4  BWP17 
VC108 Δswi4::hisG/SWI4-13MYC-HIS1 BH114 
BH440 BWP17 (pBS-CaHIS1, pBS-CaURA3)  BWP17 
VC150 Δswi4::hisG/SWI4-13MYC-HIS1, MBP1-3HA-ARG4/MBP1 VC108 
VC300 Δswi4::hisG/SWI4-3HA-URA3 BH114 
VC304 MBP1-13MYC-HIS1/MBP1 BWP17 
VC324 MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3 VC300 
VC181 CDC5-3HA-HIS1/CDC5, SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4 
YC221 
AG625 CDC5-13MYC-HIS1/CDC5 C. Bachewich 
VC348 SWI6-3HA-URA3/SWI6, CDC5-13MYC-HIS1/CDC5 AG625 
BH339 Δswi4::hisG/Δswi4::URA3 BWP17 
VC166 Δefg1::ARG4/EFG1, Δswi4::hisG/Δswi4::URA3 BH339 
VC171 Δefg1::ARG4/EFG1 BWP17 
VC199 Δefg1::ARG4/ Δefg1::HIS1, Δswi4::hisG/Δswi4::URA3 VC163 
VC200 Δefg1::ARG4/ Δefg1::HIS1 VC171 
VC380 CDC5/CDC5-3HA-HIS1, Δcln3::hisG/MET::CLN3-ARG4 BH253 
VC426 SWI6/SWI6-3HA-URA3, Δcdc5::hisG/MET::CDC5-ARG4 AG500 
YC161 (∆swi4::URA3/∆swi4::HIS1, pBS-ARG4-SWI4) BH185 
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YC171 ∆swi4::URA3/∆swi4::HIS1, pBS-ARG4 BH185 
YC201 ∆swi6::HIS1/∆swi6::URA3, pBS-ARG4-SWI6 BH120 
YC233 ∆swi6::HIS1/∆swi6::URA3, pBS-ARG4 BH120 
YC323 ∆mbp1::HIS1/∆mbp1::URA3, pBS-ARG4-MBP1 BH261 
YC381 ∆mbp1::HIS1/∆mbp1::URA3, pBS-ARG4 BH261 
BH420 BWP17, pRM100-CaURA3, CaHIS1, pBS-CaARG4 BWP17 
BH150 ∆swi4::hisG/MET3::SWI4-ARG4 BWP17 
 
Table 2. Oligonucleotides used in this study 









AG4R TCG ATG AAT TCG AGC TCG TT 
AG4F-MBP1-HA GGTCGACGGATCCCCGGGGAATACCCATACGATGTTCCT 








































































Table 3. Plasmids used in this study 
Plasmid Description Parent/Source 
pBS-CaHIS1 pBluescript CaHIS1 C.Bachewich 











2.2 Medium and Growth Conditions 
Most strains were grown at 30ºC in YPD medium containing 1% yeast extract, 2% 
peptone and 2% glucose. Conditional strains were grown at 30ºC in synthetic complete (SC) 
medium containing 0.67% yeast nitrogen base, 2% glucose and amino acids supplemented with 
or without 2.5 mM methionine and 0.5 mM cysteine for repression or induction of the MET3 
promoter, respectively [54]. All media were supplemented with 100 mg/L of uridine, histidine or 
arginine to allow optimal growth of URA3+, HIS1+ or ARG4+ auxotrophs [55], except under 
conditions of selection. For assays involving protein extraction, strains were incubated overnight 
in YPD medium at 30°C, diluted into fresh medium to an O.D.600nm of 0.1 to 0.2, and incubated 
until the O.D.600nm reached 0.8-1.0. In the case of the MET3p-CLN3 conditional strain, cells were 
incubated overnight at 30°C in SC medium lacking methionine, then diluted into fresh SC 
medium containing 2.5mM methionine and 0.5mM cysteine and incubated for 4 h to block cells 
in G1 phase.  
2.3 Construction of strains   






In order to tag the 3’ end of SWI4 with 13 copies of the MYC epitope, oligonucleotides 
YC25F and YC25R containing 70 bp homologous to regions immediately upstream and 
downstream of the SWI4 stop codon, respectively, as well as 20 bp homology to plasmid 
pMG2093 [52, 53] were used to amplify 3.9 kb fragment containing the 13MYC-HIS1 cassette. 
The PCR reaction mix was composed of 0.6 µM oligonucleotides, 0.4 mM dNTPs, 50 ng of 
pMG2093 as template, 3.75U of Expand Long Template Polymerase (Roche), and 10X Buffer 3. 
The reaction conditions were the following: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 
min, 44℃ for 1 min, 68℃ for 3 min, 45 sec, followed by a 7 min extension at 68℃ and storage at 
4℃. The product was purified using a PCR purification kit (OMEGA) and 10 g were 




In order to tag SWI4 with 3 copies of the hemagglutinin (HA) epitope at the C-terminal, 
oligonucleotides AG4F and AG4R were used to amplify a 1.7 kb HA-URA3 fragment from 
plasmid pFA-HA-CaURA3 [56]. The PCR reaction mix included 0.6 µM oligonucleotides, 0.4 
mM dNTPs, 100 ng of template, 3.75U of Expand Long Template Polymerase, and 10X Buffer 
3. The PCR reaction conditions were: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 
40℃ for 1 min, 68℃ for 1 min, 44 sec, followed by a 7 min extension at 68℃ and storage at 4℃. 
Next, oligonucleotides SWI4F1 and SWI4R1 were used to amplify a final 1.9 kb fragment from 
the product of the previous PCR reaction, consisting of HA-URA3 surrounded by 100 bp 
sequences homologous to regions flanking either side of the stop codon of SWI4. Reaction 
conditions used were: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 40℃ for 1 min, 
68℃ for 1 min, 56 sec, followed by a 7 min extension at 68℃ and storage at 4℃. The resulting 
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final product was purified and 7 g were transformed into strain BH114 (Δswi4::hisG/SWI4), 





Oligonucleotides AG4F-MBP1-HA and AG4R-MBP1-HA were used to amplify a 1.4 
kb HA-HIS1 fragment from plasmid pFA-HA-CaHIS1 [56]. The PCR reaction mix included 0.6 
µM oligonucleotides, 0.4 mM dNTPs, 100 ng of template, 3.75U of Expand Long Template 
Polymerase, and 10X Buffer 3. The reaction conditions included 94℃ for 4 min, followed by 25 
cycles of 94℃ for 1 min, 52℃ for 1 min, 68℃ for 2 min, 45 sec, followed by a 7 min extension 
at 68℃ and storage at 4℃. The resulting fragment was used as a template, with oligonucleotides 
AG29F and AG29R, in order to produce a final 2.6 kb fragment consisting of an HA-HIS1 
cassette and 100 bp sequences homologous to regions flanking either side of the stop codon of 
MBP1. The PCR reaction mix included 0.6 µM oligonucleotides, 0.4 mM dNTPs, 100 ng of 
template, 3.75U of Expand Long Template Polymerase, and 10X Buffer 3. The reaction 
conditions included 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 55℃ for 1 min, 
68℃ for 2 min, 45 sec, followed by a 7 min extension at 68℃ and storage at 4℃. The final 
product was purified, and 6.2 g were transformed into strain YC221 (SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4), resulting in strain VC132 (MBP1-3HA-HIS1/MBP1, SWI6-
TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4). 
MBP1 was similarly tagged with 3 copies of HA epitope at the C-terminus in strain 
VC108 (Δswi4::hisG/SWI4-13MYC-HIS1), with the difference of using plasmid pFA-HA-
CaARG4 in the first step PCR reaction with the following conditions: 94℃ for 4 min, followed 
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by 25 cycles of 94℃ for 1 min, 52℃ for 1 min, 68℃ for 3 min, followed by a 7 min extension at 
68℃ and storage at 4℃. The product was used as template in a second PCR reaction as described 
above, with the following conditions: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 
52℃ for 1 min, 68℃ for 3 min, 15 sec, followed by a 7 min extension at 68℃ and storage at 4℃. 
The product was purified and 5 µg were transformed into strain VC108 (Δswi4::hisG/SWI4-




In order to tag the C-terminus of MBP1 with 13 copies of the MYC epitope, 
oligonucleotides VC6F and VC6R containing 70 bp homologous to regions upstream and 
downstream of the MBP1 stop codon, respectively, as well as 20 bp homology to plasmid 
pMG2093 [52, 53] were used to amplify 3.8 kb fragment containing 13MYC-HIS1. The PCR 
reaction mix was composed of 0.6 µM oligonucleotides, 0.4 mM dNTPs, 50 ng of pMG2093 as 
template, 3.75U of Expand Long Template Polymerase, and 10X Buffer 3. The reaction 
conditions were the following: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 41℃ for 
1 min, 68℃ for 3 min, 50 sec, followed by a 7 min extension at 68℃ and storage at 4℃. The 
product was purified and 6.2 g were transformed into strains VC300 (Δswi4::hisG/SWI4-3HA-
URA3) and BWP17, resulting in strains VC324 (MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-







In order to tag SWI6 at the C-terminus with 3 copies of the HA epitope, a similar two-
step PCR strategy described for tagging SWI4 with HA was utilized, with the exception of using 
oligonucleotides SWI6F1 and SWI6R1 to amplify a final 1.9 kb fragment from the first PCR, 
consisting of HA-URA3 and 100 bp sequences homologous to regions flanking the stop codon of 
SWI6. Reaction conditions for this second PCR reaction included: 94℃ for 4 min, followed by 
25 cycles of 94℃ for 1 min, 40℃ for 1 min, 68℃ for 1 min, 56 sec, followed by a 7 min 
extension at 68℃ and storage at 4℃. The resulting final product was purified and 6.7 g were 
transformed into strain AG625 (CDC5-13MYC-HIS1/CDC5), resulting in strain VC348 (SWI6-





In order to tag CDC5 at the C-terminus with 3 copies of the HA epitope, a similar two-
step PCR strategy described for tagging SWI4 with HA was utilized, with the exception of using 
plasmid pFA-HA-CaHIS1 [56] and oligonucleotides AG4F and AG4R for the first PCR 
amplification. Reaction conditions used were: 94℃ for 4 min, followed by 25 cycles of 94℃ for 
1 min, 40℃ for 1 min, 68℃ for 1 min, 10 sec, followed by a 7 min extension at 68℃ and storage 
at 4℃. The resulting fragment was purified and used as the template with oligonucleotides AG1F 
and AG1R to amplify a final 2.0 kb fragment consisting of an HA-HIS1 cassette and 100 bp 
sequences homologous to regions flanking the stop codon of CDC5. The following reaction 
conditions were used: 94℃ for 4 min, followed by 25 cycles of 94℃ for 1 min, 40℃ for 1 min, 
68℃ for 2 min, followed by a 7 min extension at 68℃ and storage at 4℃. The final product was 
purified and 7.1 g were transformed into strains YC221 (SWI6-TAP-URA3/SWI6, 
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Δcln3::hisG/MET::CLN3-ARG4) and BH253 (Δcln3::hisG/MET::CLN3-ARG4) to obtain strains 
VC181 (CDC5-3HA-HIS1/CDC5, SWI6-TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) and 





In order to tag the C-terminus of RPN1 with 3 copies of HA in strains VC108 and 
BWP17, the two step PCR strategy described above for tagging strains with HA was utilized. 
Exceptions include use of oligonucleotides VC8F and VC8R to amplify the final 1.9 kb PCR 
product with the following reaction conditions: 94℃ for 4 min, followed by 25 cycles of 94℃ for 
1 min, 40℃ for 1 min, 68℃ for 1 min, 54 sec, followed by a 7 min extension at 68℃ and storage 
at 4℃. The resulting final product was purified and 6.0 g were transformed into strains VC108 
(Δswi4::hisG/SWI4-13MYC-HIS1) and BWP17, resulting in strains VC389 (RPN1-3HA-





In order to create a SWI4-conditional strain that lacked EFG1, both alleles were 
replaced with the ARG4 and HIS1 markers, using 2-step PCR fusion constructs. First, a 709 bp 
fragment corresponding to the 5’ flank of EFG1, located 127 bp upstream of the start codon, was 
amplified from gDNA with oligonucleotides VC1F and VC1R. The components of the PCR 
reaction mix include 0.6 µM oligonucleotides, 0.4 mM dNTPs, 100 ng of template, 3.75U of 
Expand Long Template Polymerase (Roche), and 10X Buffer 3. The following reaction 
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conditions were used: 94°C for 3 min, followed by 25 cycles of 94°C for 30 sec, 54°C for 30 sec, 
68°C for 41 sec, followed by a 7 min extension at 68℃ and storage at 4℃. Second, a 616 bp 
fragment corresponding to the 3’ flank of EFG1, located 5 bp after the stop codon, was similarly 
amplified using oligonucleotides VC2F and VC2R. The following reaction conditions were used: 
94°C for 3 min, followed by 25 cycles of 94°C for 30 sec, 53°C for 30 sec, 68°C for 35 sec, 
followed by a 7 min extension at 68℃ and storage at 4℃. To amplify the 2193 bp ARG4 
fragment from plasmid pBS-CaARG4 (H. Huang), oligonucleotides VC3F and VC3R containing 
homology to the plasmid plus additional 30 bp sequences that were the reverse complement of 
oligonucleotides VC1R and VC2F, respectively, were utilized. The components of the PCR 
reaction mix include 0.6 µM oligonucleotides, 0.4 mM dNTPs, 100 ng of pBS-CaARG4 as 
template, 3.75U of Expand Long Template Polymerase, and 10X Buffer 3. The following 
reaction conditions were used: 94°C for 3 min, followed by 25 cycles of 94°C for 30 sec, 61°C 
for 30 sec, 68°C for 2 min, 12 sec, followed by a 7 min extension at 68℃ and storage at 4℃.  
The final construct was created by amplifying a 1:2:1 (50ng:100ng:50ng) amount of the three 
PCR fragments with oligonucleotides VC1F and VC2R. The reaction mix included 0.6 µM 
oligonucleotides, 0.4 mM of dNTPs, 3.75U of Expand Long Template Polymerase, and 1X 
Buffer 3. The following reaction conditions were used: 94°C for 3 min, followed by 10 cycles of 
94°C for 10 sec, 61°C for 30 sec, and 68°C for 3 min 28 sec, followed by 15 cycles of 95°C for 
10 sec, 61°C for 30 sec, 68°C for 3 min 28 sec with a 20 sec auto-segment extension, followed 
by a 7 min extension at 68℃ and storage at 4℃. The final 3400 bp PCR product was purified and  
7.5 g or 5.6 g were transformed into strain BH339 (Δswi4::hisG/Δswi4::URA3) or BWP17, 




To delete the second copy of EFG1, a similar strategy was utilized with the exception 
of amplifying a 1404 bp HIS1 cassette fragment from plasmid pBS-CaHIS1, with 
oligonucleotides VC3F and VC3R. The following reaction conditions were used: 94°C for 3 min, 
followed by 25 cycles of 94°C for 30 sec, 61°C for 30 sec, 68°C for 1 min 24 sec, followed by a 
7 min extension at 68℃ and storage at 4℃. The final fusion construct was created by amplifying 
1:2:1 (50ng:100ng:50ng) amount of the three PCR fragments with oligonucleotides VC1F and 
VC2R in a reaction with the following conditions: 94°C for 3 min, followed by 10 cycles of 
94°C for 10 sec, 61°C for 30 sec, and 68°C for 2 min 37 sec, followed by 15 cycles of 95°C for 
10 sec, 61°C for 30 sec, 68°C for 2 min 37 sec with a 20 sec auto-segment extension, followed 
by a 7 min extension at 68℃ and storage at 4℃. The final 2611 bp product was purified and 6.25 
g or 6.35 g were transformed into strains VC166 (Δefg1::ARG4/EFG1, 
Δswi4::hisG/Δswi4::URA3) and VC171 (Δefg1::ARG4/EFG1), resulting in strains VC199 
(Δefg1::ARG4/Δefg1::HIS1, Δswi4::hisG/Δswi4::URA3) and VC200 (Δefg1::ARG4/ 
Δefg1::HIS1), respectively. 
2.4 Transformation 
C. albicans was transformed according to [57], with a few modifications. Briefly, the 
One-Step-Buffer (OSB) consisted of 25 l of 10 mg/ml salmon sperm DNA (ssDNA) 
(Invitrogen), 0.0154g of dithiothreital (DTT), 800 l of 50% PEG 4000 (Sigma) and 200 l of 1 
M lithium acetate. A pellet obtained from centrifuging 300 l of an overnight cell culture at 
13,000 rpm for 3 min was washed with sterile water and re-suspended in 100 l of OSB solution. 
A maximum volume of 10 l of approximately 5-7 g of DNA was added. The mixture was 
vortexed for 1 min, incubated overnight at 30C, heat-shocked at 43℃ for 1 h and plated on 
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selective solid medium. Transformants were subsequently streaked to single colony three times 
before screening. For strains containing CLN3 under control of the MET3 promoter, cells were 
grown overnight in an inducing medium lacking methionine and cysteine (-MC), then transferred 
into rich YPD medium for 2 h prior to collection, to increase the transformation efficiency.  
2.5 Genomic DNA extraction 
For gDNA extraction, the method of [58] was utilized. Briefly, cells were inoculated 
into 5 ml of YPD medium or -MC medium that lacked methionine and cysteine, and incubated 
overnight at 30C. Cell cultures were then centrifuged for 5 min at 3000 rpm, the pellet was 
washed with 700 l sterile distilled water, and re-suspended in 1 ml of sorbitol buffer (1M 
sorbitol, 0.1M EDTA) followed by the addition of 10 l of lyticase ((10U/l); Sigma) and 2 l of 
4.0 M DTT. The mixture was incubated at 37C for 1.5 h, centrifuged for 2 min at 13500 rpm, 
and the supernatant was removed. The pellet was re-suspended in 200 l Tris-EDTA solution (50 
mM Tris, 20 mM EDTA), and SDS was added to 1%. Cells were incubated at 65C for 30 min, 
followed by the addition of 100 l of 5.0 M potassium acetate (KAc). This mixture was 
incubated on ice for 60 min, and centrifuged for 10 min at 13500 rpm. An equal amount of 100% 
isopropanol was added to the supernatant. The samples were mixed for 1 min, centrifuged at 
13500 rpm for 1 min, and the resulting DNA pellet was washed with 70% ethanol. After air-
drying,  the pellet was re-suspended into 100 l of TE buffer (1 mM EDTA, 10 mM Tris-HCl pH 
8.0) with 2 l of RNaseA (10 mg/ml), and  incubated at 37C for 30 min. The concentration of 





2.6 Screening transformants 
Transformants were screened for correct integration of DNA constructs using PCR. The 
PCR reaction mix consisted of 0.6 µM of oligonucleotides, 0.4 mM of dNTPs, 100 ng of gDNA 
as template, 3 mM of MgCl2, 1X Taq Buffer with (NH4)2SO4 and 5 U Taq DNA Polymerase 
(Fermentas). Confirmation of strain VC108 (Δswi4::hisG/SWI4-13MYC-HIS1) was done using 
oligonucleotides YC21F located 743 bp upstream and BH14R which locates 766 bp downstream 
of stop codon to amplify a 5000 bp product. For this screening, 3.75U of Expand Long Template 
Polymerase (Roche) and 10X buffer were used due to the large PCR product size. The following 
reaction conditions were used: 94℃ for 3min, 30 cycles of 94℃ for 30 sec, 48℃ for 30 sec, 68℃ 
for 5 min, followed by a 7 min extension at 68℃ and storage at 4℃. To confirm strain VC132, 
oligonucleotides CaHIS1F (located inside the plasmid pFA-HA-CaHIS1), and AG30R (located 
427 bp downstream of stop codon of MBP1) were used to amplify a 1923 bp product. The 
reaction conditions used were as follows: 95℃ for 3min, 30 cycles of 95℃ for 30 sec, 42℃ for 
30 sec, 72℃ for 2 min 32 sec, followed by a 7 min extension at 72℃ and storage at 4℃. Strain 
VC150 was confirmed with oligonucleotides CaARG4F, located inside the plasmid pFA-HA-
CaARG4 and YC15R, located 224 bp downstream of stop codon of MBP1, to amplify a 1264 bp 
product. The following reaction conditions were used: 95℃ for 3 min, 30 cycles of 95℃ for 30 
sec, 36℃ for 30 sec, 72℃ for 1 min 16 sec, followed by a 7 min extension at 72℃ and storage at 
4℃. Confirmation of strain VC300 was done by using oligonucleotides SWI4SF1, which locates 
145 bp upstream of stop codon of SWI4, and SWI4SR1, which locates 252 bp downstream of 
stop codon of SWI4, to amplify a 2046 bp product. The reaction conditions used were as follows: 
94℃ for 3 min, 30 cycles of 94℃ for 30 sec, 44℃ for 30 sec, 68℃ for 2 min 3 sec, followed by a 
7 min extension at 68℃ and storage at 4℃. The strain VC324 was confirmed by using 
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oligonucleotides CaHIS1F, located inside the plasmid pMG2093 and YC15R, located 224 bp 
downstream of stop codon of MBP1, to amplify a 970 bp product. The following reaction 
conditions were used: 95℃ for 3 min, 30 cycles of 95℃ for 30 sec, 36℃ for 30 sec, 72℃ for 58 
sec, followed by a 7 min extension at 72℃ and storage at 4℃. Confirmation of strain VC181 was 
done by using oligonucleotides CaHIS1F (located inside the plasmid pFA-HA-CaHIS1) and 
AG2R, which locates 258 bp downstream of stop codon of CDC5, to amplify a 1773 bp product. 
The following reaction conditions were used: 95℃ for 3 min, 30 cycles of 95℃ for 30 sec, 38℃ 
for 30 sec, 72℃ for 1 min 46 sec, followed by a 7 min extension at 72℃ and storage at 4℃. The 
strain VC348 was confirmed by using oligonucleotides CaURA3F (located inside the plasmid 
pFA-HA-CaURA3) and SWI6SR1, located 307 bp downstream of stop codon of SWI6, to 
amplify an 898 bp product. Confirmation of VC163 and VC171 was done by using 
oligonucleotides VC4F, located 920 bp upstream of start codon of EFG1 and CaARG4R, located 
inside the plasmid pFA-HA-CaARG4, to amplify a 1200 bp product. The reaction conditions 
used were as follows: 95℃ for 3 min, 30 cycles of 95℃ for 30 sec, 38℃ for 30 sec, 72℃ for 2 
min 10 sec, followed by a 7 min extension at 72℃ and storage at 4℃. The strains VC199 and 
VC200 were confirmed using oligonucleotides VC4F, located 920 bp upstream of start codon of 
EFG1 and CaHIS1R, located inside the plasmid pFA-HA-CaHIS1, to amplify a 1348 bp product. 
The following reaction conditions were used: 95℃ for 3 min, 30 cycles of 95℃ for 30 sec, 38℃ 
for 30 sec, 72℃ for 1 min 21 sec, followed by a 7 min extension at 72℃ and storage at 4℃. 
Confirmation of VC389 and VC394 was done using oligonucleotides CaURA3F, located inside 
the plasmid pFA-HA-CaURA3 and VC9R, located 225 bp downstream of stop codon of RPN1, 
to amplify an 892 bp product. Reaction conditions used were as follows: 95℃ for 3 min, 30 
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cycles of 95℃ for 30 sec, 36℃ for 30 sec, 72℃ for 54 sec, followed by a 7 min extension at 72℃ 
and storage at 4℃. 
2.7 Protein extraction and Western blotting 
Protein was extracted according to the method outlined in [59]. Briefly, cells were 
inoculated into 2 ml of YPD or -MC minimal medium, incubated overnight at 30C, diluted to an 
OD600nm of 0.1 into a final volume of 50 ml, and incubated at 30C until an OD600nm of 0.8-1.0 
was reached. Cell pellets were obtained by centrifugation for 5 min at 3000 rpm. The pellets 
were washed with sterile water, lyophilized for 24 h in a freeze dryer (ThermoSavant, Modulyo 
D), and ground to a fine powder using a sterile toothpick. Subsequently, 1 ml of cold HK buffer 
(25 mM TRIS pH7.5, 0.5% NP40, 300 mM NaCl, 5 mM EDTA pH8.0, 15 mM EGTA pH8.0, 60 
mM Beta Gly.PO4, 500 M Na Vanadate, 10 mM Na Fluoride, 1 g/ml Pepsatin A, 10 g/ml 
Leupeptin, 10 g/ml Trypsin ChymoT inhibitor, 10 g/ml Aprotinin, 10 g/ml TPCK, 2 mM 
TAME, 5 mM Benzamidine, 250 g/ml PMSF, 1 mM DTT) per 0.8 g dry weight was added.  
The samples were vortexed 4X 10 sec with a 3 min break on ice in between rounds, and 
centrifuged at 13,500 rpm for 10 min at 4°C to remove cell debris. The supernatant was then 
centrifuged at 13,500 rpm for 30 min (for Western confirmation, but 1 h for Co-IPs) at 4°C and 
stored at -80°C. Protein concentration was determined using the Bradford assay. 
 For Western blotting, 30 g of protein was separated on 7.5% SDS PAGE gels, and 
transferred to a polyvinyl difluoride (PVDF) membrane (BIO-RAD) overnight at 30V and 4C. 
The membrane was air-dried completely, incubated in blocking solution (5% milk in 1X TBST 
with 0.05% Tween-20) for 90 min, washed 3 x with 1X TBST (50 mM Tris, 0.15 M NaCl, 
0.05% Tween-20, pH 7.6) for 10 min each, followed by incubation with primary antibody diluted 
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in 1X TBST for 2 h. Primary antibodies included mouse monoclonal antibody clone 9E10 IgG 
(Roche Diagnostics, 1:1000 dilution) and mouse monoclonal antibody clone 12CA5 (Roche 
Diagnostics, 1:500 dilution). The membrane was washed 3 x with 1X TBST for 10 min each, and 
then incubated with secondary antibody (Goat anti-rabbit IgG-HRP, Santa Cruz Biotechnology, 
1:10000 dilution) for 1 h. After washing 3 x with 1X TBST for 10 min each, signal was detected 
with chemiluminescence using ECL (GE Healthcare). Membranes were stripped in 15 ml of 
stripping solution (0.4% SDS, 1.2 mM Tris pH 6.8, 0.25g DTT) for 30 min at 50C. 
2.8 Co-Immunoprecipitation (Co-IP) 
Cultures were obtained and protein extracted as described above with the exception that 1 
L culture volumes were utilized. For Co-IP, Mono HA 11 Affinity beads (Covance), mouse 
monoclonal anti-Myc on Sepharose beads (Covance) or IgG Sepharose 6 Fast Flow beads (GE 
Healthcare) were utilized. Briefly, volumes of bead slurry were centrifuged at 1500 x g for 2 min 
at 4°C to remove the buffer, and washed 3 x in 500 μl of HK buffer. The beads were then 
suspended in fresh HK buffer and combined with protein. For 40, 20 or 2 mg of protein, 60, 40 
or 10 l of bead slurry were utilized, respectively. The samples were incubated overnight at 4°C 
with rocking, centrifuged at 1500 x g for 2 min at 4°C, and washed 5 x with 1 ml HK buffer.  
Protein was then eluted from beads by boiling in same amount as bead volume plus an additional 
10 l of 1X SDS sample buffer (50 mM Tris pH 6.8, 2% SDS, 0.01% Bromophenol blue, 10% 
Glycerol, 100mM DTT) for 10 min. The samples were centrifuged for 2 min at 13500 rpm at 
room temperature. The bead pellets were boiled again in same amount of 1X SDS sample buffer 
as bead volume (1:1) for 10 min. Samples were subsequently loaded onto SDS PAGE gels for 




2.9 RNA extraction and Northern blotting 
For RNA extraction, 50 ml of culture at an OD600nm of 0.8-1.0 were collected through 
centrifugation for 5 min at 5000 rpm. The pellet was washed with sterile water and lyophilized in 
a freeze dryer. Freeze-dried cell pellet was ground to fine powder using a sterile toothpick and 
RNA extracted according to [60]. Briefly, 1 ml of TRI reagent (Molecular Research Center, Inc.) 
was added to 100 l of dried pellet. The samples were vortexed 10 x, 10 sec followed by 
incubation for 5 min at room temperature. After addition of 0.2 ml of chloroform, samples were 
shaken vigorously for 15 sec, incubated at room temperature for 5 min, and then centrifuged at 
12000 x g for 15 min at 4°C. The supernatant was transferred to new Eppendorf tubes, to which 
0.5 ml of cold isopropanol was added. The tubes were inverted 3 x, incubated on ice for 5 min, 
then centrifuged at 12000 x g for 8 min at 4°C. The resulting RNA pellet was washed twice with 
1 ml of ice-cold 70% DEPC-treated ethanol, and tubes were left on ice for 5 min for complete 
evaporation. The RNA pellet was re-suspended in 60 l of ice-cold DEPC-treated water by 
incubation at 60°C for 10 min. To re-precipitate the RNA, one-tenth volume of 3M sodium 
acetate and 3X the volume of 100% ethanol were added and samples were stored at -20°C 
overnight. Samples were subsequently centrifuged at 13000 rpm for 10 min at 4°C to remove 
ethanol followed by washing 2 x with 70% DEPC-treated ethanol. The pellet was then air-dried 
and dissolved with 50 μl DEPC water. The concentration of samples was next measured using a 
spectrophotometer.  
 Northern blotting was performed according to [61]. DNA probes were amplified by 
PCR. The reaction mix consisted of 0.6 µM oligonucleotides, 0.4 mM dNTPs, 100 ng of gDNA, 
3.75U of Expand Long Template Polymerase (Roche), and 10X Buffer 3. The EFG1 probe 
utilized oligonucleotides EFG1F1 and EFG1R1 with the following reaction conditions: 94℃ for 
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4 min, followed by 25 cycles of 94℃ for 1 min, 40℃ for 1 min, 68℃ for 1 min, 10 sec, followed 






3.1 Organization of the G1/S transcription factor complex 
3.1.1 Co-immunoprecipitation utilizing low amounts of input protein confirms that Swi6p 
physically interacts with Swi4p and Mbp1p. 
Previous work from the Bachewich lab (Y. Chen, MSc thesis) showed that Swi6p was the 
major interacting factor of Swi4p and Mbp1p via affinity purification and mass spectrometry 
analyses. These physical interactions were subsequently confirmed via Co-IP. However, 40 mg 
of protein was used for these experiments. In order to determine whether the physical 
interactions could be detected with lower amounts of protein, I repeated the Co-IPs with 2 mg of 
protein. For testing an interaction between Swi4p and Swi6p, strains AH110 (SWI4-3HA-HIS1/ 
SWI4, Δswi6::URA3/SWI6-TAP-ARG4), AM201.5 (Δswi6::URA3/SWI6-TAP-ARG4), and 
YC113 (Δswi4::hisG/SWI4-3HA-HIS1) were incubated at 30 C until they reached an O.D. 600nm 
of 0.8, collected and protein was extracted. A total of 2 mg was incubated with anti-HA or IgG-
sepharose beads for Co-IP reactions. When Swi4p-3HA was precipitated with anti-HA beads, 
Swi6p-TAP co-purified (Fig. 4A). Furthermore, Swi4p-3HA was present in the pull down when 
Swi6p-TAP was precipitated with IgG sepharose (Fig. 4B). The detection of either protein in 
reciprocal Co-IPs using lower amounts of input protein supports a physical interaction.  
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In order to determine whether an interaction between Swi6p and Mbp1p could also be 
detected with lower input levels of protein, strains YC396 (MBP1-TAP-ARG4/MBP1, 
Δswi6::HIS1/SWI6-3HA-URA3), YC367 (Δmbp1::HIS1/MBP1-TAP-URA3), and YC216 
(Δswi6::HIS1/SWI6-3HA-URA3) were utilized in Co-IP experiments as described above. When 
Swi6p-3HA was precipitated from 2 mg of protein with anti-HA beads, Mbp1p-TAP co-purified 
(Fig. 5A). In addition, when Mbp1p-TAP was precipitated with IgG sepharose, Swi6p-3HA was 
detected (Fig. 5B). Thus, Swi6p also strongly interacts with Mbp1p.  
Previous work showed that Mbp1p was not among the enriched peptides that co-purified 
with Swi6p when affinity purified from cells blocked in G1 phase (Y. Chen, MSc thesis). In 
order to confirm whether Swi6p and Mbp1p interact during G1 phase, a Co-IP was performed. 
For this, a strain carrying a conditional allele of the G1 cyclin CLN3 and one allele of SWI6 
tagged with TAP (YC221; SWI6-TAP-URA3/SWI6, ∆cln3::hisG/MET::CLN3-ARG4),  was 
transformed with a DNA construct that would tag a single copy of MBP1 at the C-terminus with 
three copies of HA, resulting in strain VC132 (MBP1-3HA-HIS1/MBP1, SWI6-TAP-URA3/SWI6, 
∆cln3::hisG/MET::CLN3-ARG4) (Fig. 6). Strains VC132 and control strain YC221 were 
incubated in inducing (-MC) media overnight, then diluted into repressing (+MC) media and 
incubated at 30C for 4 h. When Mbp1p-3HA was pulled out using anti-HA beads, Swi6p-TAP 
co-purified (Fig. 7), suggesting that the proteins do interact in G1-phase-blocked cells. A reverse 
Co-IP using IgG beads was not done due to strong non-specific cross-reaction problems 
associated with the TAP tag. Thus, Swi6p interacts with Mbp1p in G1 phase cells. 
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3.1.2 Swi4p and Mbp1p do not physically interact in the manner that Swi6p binds Swi4p or 
Mbp1p. 
Since Swi6p binds both Swi4p and Mbp1p, this suggests that C. albicans may either 
contain two separate complexes, as seen in S. cerevisiae or one complex that includes Mbp1p. In 
the case of the latter, it is predicted that Swi4p and Mbp1p should physically interact. However, 
previous attempts to test for this interaction were inconclusive. Although Swi4p-HA co-purified 
with Mbp1p-TAP that was pulled out from 40 mg of protein (Y. Chen thesis), the proteins were 
similar in size, and the reverse Co-IP showed non-specific binding to beads. Further, when a 
strain carrying Swi4p-5MYC and Mbp1p-3HA was utilized, Swi4p-5MYC did not co-purify 
with affinity-purified Mbp1p-3HA. In order to further address this question, a new strain was 
constructed whereby a single copy of SWI4 in strain BH114 (Δswi4::hisG/SWI4) was tagged 
with 13 copies of MYC at the C-terminus in order to enhance the MYC detection, resulting in 
strain VC108 (Δswi4::hisG/SWI4-13MYC-HIS1). Western blotting confirmed that the protein 
was expressed (Fig. 8). Next, MBP1 was tagged with 3 copies of HA in strain VC108, resulting 
in strain VC150 (Δswi4::hisG/SWI4-13MYC-HIS1, MBP1-3HA-ARG4/MBP1) (Fig. 9). Strains 
VC150, VC108 and YC351 (Δmbp1::HIS1/MBP1-3HA-URA3) were subsequently used for Co-
IP experiments. When Mbp1p-3HA was precipitated from 40 mg of protein with anti-HA beads, 
Swi4p-13MYC was not present in the pull down, suggesting that these two proteins do not 
interact (Fig. 10A). In contrast, a reverse Co-IP using anti-MYC beads to precipitate Swi4p-
13MYC was inconclusive, since there was strong non-specific cross-reaction in the control strain 
(Fig. 10B). In order to determine whether the anti-MYC beads would bind other proteins non-
specifically, immunoprecipitation with anti-MYC beads was performed with strain YC101 
(SWI4-3HA-HIS1/SWI4) and a second strain containing MBP1-3HA, YC352 
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(Δmbp1::HIS1/MBP1-3HA-URA3). When immune extracts were incubated with anti-HA 
antibody, Swi4p-3HA was not detected, in contrast to Mbp1p-3HA (Fig. 11). This suggests that 
the anti-MYC beads were unexpectedly interacting with Mbp1p-3HA.  
In order to determine whether the issues of non-specific interaction between the anti-
MYC beads and Mbp1p-3HA were specific to the strain used, a new strain was constructed 
whereby SWI4 was tagged with 3 copies of HA at the C-terminus in strain BH114 
(Δswi4::hisG/SWI4), resulting in strain VC300 (Δswi4::hisG/SWI4-3HA-URA3) (Fig. 12). Next, 
the C-terminus of MBP1 was tagged with 13 copies of MYC in strains BWP17 and VC300, 
resulting in strains VC304 (MBP1-13MYC-HIS1/MBP1) and VC324 (MBP1-13MYC-
HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3) (Fig. 13 and Fig. 14). When Swi4p-3HA was 
precipitated with anti-HA beads from 40 mg of protein, Mbp1p-13MYC was present in the pull 
down, suggesting that these two proteins interact (Fig. 15A). In contrast, the reverse Co-IP 
showed that when Mbp1p-13MYC was precipitated with anti-MYC beads, Swi4p-3HA did not 
co-purify (Fig. 15B). Furthermore, there was no non-specific cross-reaction observed between 
anti-MYC beads and Swi4p-3HA control strain. 
In order to determine whether the interaction between Swi4p and Mbp1p could be 
detected with lower amounts of input protein, similar to that observed with Swi6p and Swi4p or 
with Mbp1p, the Co-IP was repeated with 2 mg of protein. When Swi4p-3HA was precipitated 
with anti-HA beads, Mbp1p-13MYC did not co-purify (Fig. 16A). The reverse Co-IP using anti-
MYC beads also showed absence of Swi4p-3HA in the Mbp1p-13MYC precipitate (Fig. 16B).  
However, a strong band was observed in the control lane, indicating that the anti-MYC beads in 
my hands bound non-specifically to Swi4p-3HA in this trial, and that the non-specific cross-
 35 
 
reaction was not specific to Mbp1p-HA as seen in Figure 6. Thus, only the Co-IPs using anti-HA 
beads were conclusive. 
  Collectively, the data show that Swi4p and Mbp1p can interact but only with high 
amounts of input protein and only when Swi4p is pulled out. The lack of interaction between 
Swi4p and Mbp1p with lower amounts of input proteins indicates that that the interaction is not 
the same as that seen between Swi6p and Swi4p or Swi6p and Mbp1p, raising the possibility of 
there being two separate Swi6p-containing complexes in C. albicans.  
3.1.3 Validation of other proteins that interact with Swi6p: Cdc5p  
 
Previous work involving affinity purification of Swi6p followed by mass spectrometry 
identified additional proteins that may interact with Swi6p (Y. Chen, MSc thesis), including the 
mitotic polo-like kinase Cdc5p [43, 46]. The putative interaction was identified in cells arrested 
in G1 phase, but not in exponential-phase cells. Since this interaction has not been previously 
reported, we attempted to confirm the result via Co-IP. For this, CDC5 was tagged with three 
copies of HA at the C-terminus in strain YC221 (SWI6-TAP-URA3/SWI6, 
∆cln3::hisG/MET::CLN3-ARG4), to obtain strain VC181 (CDC5-3HA-HIS1/CDC5, SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) (Fig. 17). Next, a control strain VC380 (CDC5-
3HA-HIS1/CDC5, Δcln3::hisG/MET::CLN3-ARG4) was constructed by tagging CDC5 with an 
HA tag in strain BH253 (Δcln3::hisG/MET::CLN3-ARG4) (Fig. 18). Strains VC181 and VC380 
were incubated in inducing (-MC) media overnight, diluted into repressing (+MC) media and 
incubated at 30C for 4 h. When Cdc5p-3HA was precipitated using anti-HA beads, Swi6p-TAP 
co-purified, indicating that these two proteins interact in G1 phase-arrested cells (Fig. 19A).  
However, a reverse Co-IP that pulled out Swi6p-TAP was inconclusive as strong non-specific 
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cross-reaction was noted in the control sample (Fig. 19B). In order to determine whether these 
Swi6p and Cdc5p interact in exponential phase cells, Co-IP was repeated under these growth 
conditions, using the same strains. When Cdc5p-3HA was precipitated with anti-HA beads, a 
band that cross-reacted with the anti-TAP antibody was present, but also in the control strain 
(Fig. 20). Thus, the result is inconclusive due to non-specific binding of beads.  
In an attempt to eliminate non-specific cross-reaction and further investigate whether 
Swi6p and Cdc5p interact in exponential-phase cells, new strains with different tags were created 
and the Co-IP was repeated. For this, SWI6 was tagged with three copies of HA at the C-
terminus in a strain that contained CDC5 tagged with 13 copies of MYC (AG629; CDC5-
13MYC-HIS1/CDC5) to obtain strain VC348 (SWI6-3HA-URA3/SWI6, CDC5-13MYC-
HIS1/CDC5). VC348 was confirmed by PCR and Western blot analysis (Fig. 21). When Swi6p-
3HA was pulled out with anti-HA beads, a very faint band corresponding to Cdc5p-13MYC was 
detected (Fig. 22A). Reverse Co-IP using anti-MYC beads to pull out Cdc5p-13MYC revealed 
non-specific cross-reaction in the control strain and was thus inconclusive (Fig. 22B).   
Since an interaction between Swi6p and Cdc5p was detected in cells blocked in G1 phase 
via affinity purification followed by mass spectrometry, and in one Co-IP experiment, we further 
explored the interaction by asking whether Swi6p was post-translationally modified by Cdc5p. In 
order to test this hypothesis, SWI6 was tagged with three copies of HA tag in a strain containing 
one copy of CDC5 under the control of MET3 promoter (AG500; Δcdc5::hisG/MET3::CDC5-
ARG4), resulting in strain VC426 (SWI6-3HA-URA/SWI6, Δcdc5::hisG/MET3::CDC5-ARG4).  
VC426 was confirmed via PCR and Western analysis (Fig. 23). Next, strains VC426 and control 
strain YC216 (Δswi6::HIS1/SWI6-3HA-URA3) were diluted to an O.D.600nm of 0.0001 and 
incubated overnight at 30o in inducing (-MC) media. The next day, when cells reached 
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exponential phase (O.D. of 0.8), they were diluted to an O.D.600nm of 0.3 in fresh inducing (-MC) 
or repressing (+MC) media, and collected at 0, 3, or 6 h. Swi6p was then analyzed via Western 
blotting (Fig. 24). However, Swi6p did not show significant changes in migration in the presence 
vs. absence of Cdc5p. The levels of Swi6p appeared to decrease as Cdc5p was depleted, but 
quantification was not done and we cannot rule out differences in loading. Overall, the results 
suggest that Swi6p may physically interact with Cdc5p, but the functional significance of this 
relationship remains unclear.  
Other additional Swi6p-interacting factors identified in previous studies include an 
unknown orf, orf19.5722, which contains a domain with DNA binding activity and has a role in 
regulation of transcription (Table 4). A physical interaction between these two proteins still 
requires confirmation via Co-IP. 
3.1.4 Confirmation of additional interacting factors of Swi4p: components of the 
proteasome  
Although Swi6p was previously identified to be the dominant interacting factor of Swi4p 
(Y. Chen MSc thesis), several other putative interacting proteins with functions related to the 
proteasome were identified, including Pr26p, a sub-unit of the 26S proteasome, and Rpn1p, 
Rpn3p, Rpt6p, which are components of the 19S regulatory subunit (Table 5). The 19S 
proteasome is responsible for removing ubiquitin chains and subsequently transferring target 
proteins into the inner core of 26S proteasome [62]. A physical interaction between Swi4p and 
the proteasome has not been previously reported. These results may have important implications 
for divergent Swi4p regulation in C. albicans. In order to first confirm the interactions, RPN1 
was tagged with a three copies of HA at the C-terminus in a 13-MYC tagged SWI4 strain 
(VC108), resulting in strain VC389 (RPN1-3HA-URA3/RPN1, Δswi4::hisG/SWI4-13MYC-
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HIS1), which was confirmed via PCR and Western blot (Fig. 25). The control strain VC394 
(RPN1-3HA-URA3/RPN1) was also constructed and confirmed via PCR and Western (Fig. 26) to 
use as a control. The strains in hand will now allow for a Co-IP experiment and further 
investigation of a putative role for the proteasome in Swi4p regulation.  
3.2 Validation of putative Swi4p targets: EFG1 
3.2.1 Expression of EFG1 is moderately induced as Swi4p is depleted over time 
In order to determine the mechanisms of action of Swi4p, a previous study (Y. Chen, 
MSc thesis) completed a genome-wide location analysis of Swi4p using a single tiling array. 
Results showed significant enrichment of Swi4p binding at promoter regions of genes associated 
with budding pattern, cell wall biogenesis, and cell cycle transitions. Intriguingly, most of the 
genes were linked to biological processes associated with filamentous growth, and included 
important regulators of hyphal development. One target was EFG1, a transcription factor that is 
required for hyphal growth under most hyphal-inducing conditions [37, 63]. Together with the 
fact that yeast cells depleted of Swi4p grow predominantly in a filamentous fashion, the data 
suggests that Swi4p and the G1/S cell cycle machinery may directly impinge on the hyphal 
development program. In order to gain additional evidence supporting this hypothesis, we 
investigated the functional significance of Swi4p occupation of the EFG1 promoter. First, we 
asked whether EFG1 expression was modulated in the absence of Swi4p. For this, strains YC161 
(∆swi4::URA3/∆swi4::HIS1, pBS-ARG4-SWI4), YC171 (∆swi4::URA3/∆swi4::HIS1, pBS-
ARG4), YC201 (∆swi6::HIS1/∆swi6::URA3, pBS-ARG4-SWI6), YC233 
(∆swi6::HIS1/∆swi6::URA3, pBS-ARG4), YC323 (∆mbp1::HIS1/∆mbp1::URA3, pBS-ARG4-
MBP1), YC381 (∆mbp1::HIS1/∆mbp1::URA3, pBS-ARG4), and BH420 (BWP17, pRM100-
CaURA3, CaHIS1, pBS-CaARG4) were incubated in minimal complete media until they reached 
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an OD600nm of 0.8. Cells were collected, RNA was extracted and EFG1 expression was 
determined using Northern blotting. The levels of EFG1 did not significantly vary between 
strains (Fig. 27A).  
In order to further investigate EFG1 expression, we next determined whether it was 
modulated within a window of Swi4p depletion, since EFG1 in C. albicans decreases rapidly in 
response to serum but resumes expression at later stages [64]. For this, strain BH150 
(∆swi4::hisG/MET3::SWI4-ARG4) and the control strain BH420 (SWI4/SWI4) were incubated in 
inducing (-MC) medium at 30C overnight, diluted into repressing (+MC) or  inducing medium 
and incubated for set times. Cells were collected, RNA was extracted and a Northern blot was 
completed. Under these conditions, EFG1 was moderately induced as Swi4p was depleted 
overtime (Fig. 27B). Time “0” time points had little RNA, as observed for both EFG1 and the 
ACT1 loading control, which reflects the difficulty in extracting RNA from stationary phase 
culture cells. Thus, EFG1 is moderately induced in cells depleted of Swi4p.   
3.2.2 Absence of EFG1 partially suppresses the phenotype of swi4Δ/swi4Δ cells 
 
We further tested the functional significance of Swi4p occupation of the EFG1 promoter 
by asking if Efg1p was required for the filamentous phenotype of Swi4p-depleted cells. For this, 
two alleles of EFG1 were replaced with ARG4 and HIS1 markers in strain BH339 
(swi4::hisG/swi4::URA3), resulting in strain VC247. Strains were confirmed by PCR, which 
show two distinct bands corresponding to two EFG1 alleles replaced by markers (Fig. 28A and 
B). Importantly, the wild-type EFG1 allele was not present (Fig. 28C). Next, strains VC247 and 
VC166 (Δefg1::ARG4/EFG1, Δswi4::hisG/Δswi4::URA3) were investigated for phenotype.  
Heterozygous strain VC166 showed long filaments and enlarged, oval-shaped cells (Fig. 29), as 
shown previously for Swi4p-depleted cells [48]. However, cells of strain VC247 were short, 
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spindle-like, and not enlarged, suggesting partial suppression of the Swi4p-depleted filamentous 
phenotype (Fig. 29). Together, the results demonstrate that EFG1 expression is influenced by 
Swi4p, and the Swi4p-depleted phenotype is dependent in part on Efg1p. This supports the idea 






















Figure 4. Co-immunoprecipitation demonstrates a positive interaction between Swi6p and 
Swi4p. 
Western blot of whole cell extract and immune-precipitates from strains AM201.5 
(∆swi6::URA3/SWI6-TAP-ARG4), AH110 (SWI4-3HA-HIS1/SWI4, Δswi6::URA3/SWI6-TAP-
ARG4) and YC113 (∆swi4:hisG/SWI4-3HA-HIS1) using anti-HA agarose (A) or IgG sepharose 
(B). 20 µl of beads were incubated with 2 mg of protein overnight, washed, and boiled in SDS 













Figure 5. Co-immunoprecipitation demonstrates a positive interaction between Swi6p and 
Mbp1p. 
Western blot of whole cell extract and immune-precipitates from strains YC367 
(∆mbp1::HIS1/MBP1-TAP-URA3), YC396 (∆swi6::HIS1/SWI6-3HA-URA3, MBP1/MBP1-TAP-
URA3) and YC216 (∆swi6::HIS1/SWI6-3HA-URA3) using anti-HA agarose (A) or IgG 
sepharose (B). 20 µl of beads were incubated with 2 mg of protein overnight, washed, and boiled 












Figure 6. Construction of a strain carrying MBP1-3HA in a SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4 background. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-HIS1-containing 
construct at the C-terminus of MBP1. Oligonucleotides CaHIS1F and AG30R produced a 1923 
bp band for MBP1-3HA. Positive strains VC132, VC133, VC134, and VC135 (MBP1/MBP1-
3HA-HIS1, SWI6-TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) and negative control strain 
BWP17 are shown in (B). (C) Western blot containing 30 µg of protein from strains VC132, 
VC133, VC134, VC135, YC113 (MBP1-3HA-HIS1/MBP1, SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4), and BWP17 incubated with anti-HA antibody. Mbp1-3HA is 









Figure 7. Co-immunoprecipitation confirming an interaction between Mbp1p and Swi6p in 
G1 phase-blocked cells. 
Western blots of whole cell extracts and immune-precipitates from strains YC221 (SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) and VC132 (MBP1-3HA-HIS1/MBP1, SWI6-
TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) grown in repressing medium (+MC) for 4 h 
to induce a G1-phase block, using anti-HA agarose.  40 mg of protein was incubated with 40 µl 



















Figure 8. Confirmation of a Δswi4::hisG/SWI4-13MYC-HIS1 strain. 
(A, B) Map and gel of a PCR screen to confirm intergration of a 13MYC-HIS1-containing 
construct at the C-terminus of SWI4. Oligonucleotides YC21F and BH14R amplify a 5 kB band 
for SWI4-13MYC and a 1.4 kB band for SWI4/SWI4 (A). Positive strain VC108 
(Δswi4::hisG/SWI4-13MYC-HIS1) and negative control strain BWP17 are shown in (B). (C) 
Western blot containing 30 µg of whole cell protein extracts from strains VC104, VC108, 
VC112 (Δswi4::hisG/SWI4-13MYC-HIS1), AG625 (CDC5-13MYC-HIS1/CDC5), and BWP17 





Figure 9. Construction of a strain carrying MBP1-3HA-ARG4 and SWI4-13MYC-HIS1. 
(A, B) Map and gel of a PCR screen to confirm intergration of a 3HA-ARG4-containing construct 
at the C-terminus of MBP1. Oligonucleotides CaARG4F and YC15R amplify a 1264 bp band for 
MBP1-3HA (A). Positive strains VC150 and VC151 (Δswi4::hisG/SWI4-13MYC-HIS1, 
MBP1/MBP1-3HA-ARG4) are shown in (B). (C) Western blot containing 30 µg of whole cell 
protein extracts from strains VC150, VC151, VC159 and VC160 (Δswi4::hisG/SWI4-13MYC-
HIS1, MBP1/MBP1-3HA-ARG4), YC113 (Δswi4::hisG/SWI4-3HA-HIS1), and BWP17 incubated 















Figure 10. Co-immunoprecipitation demonstrates a negative interaction between Mbp1p 
and Swi4p when Mbp1p is immune-precipitated. 
Western blot of whole cell extract and immune-precipitates from strains VC108 
(Δswi4::hisG/SWI4-13MYC-HIS1), VC150 (Δswi4::hisG/SWI4-MYC-HIS1, MBP1/MBP1-HA-
ARG4) and YC351 (Δmbp1::HIS1/MBP1-3HA-URA3) using anti-HA agorose (A) or anti-MYC 
agarose (B). 40 µl of beads were incubated with 40 mg of protein overnight, washed, and boiled 










Figure 11. Co-immunoprecipitation shows that non-specific cross reaction of anti-MYC 
beads is specific to Mbp1p tagged with an HA tag. 
Western blot of whole cell extract and immune-precipitates from strains YC352 
(Δmbp1::HIS1/MBP1-3HA-URA3) and YC101 (SWI4-3HA-HIS1/SWI4) using anti-MYC 
agarose. 40 µl of beads were incubated with 40 mg of protein overnight, washed, and boiled in 












Figure 12. Confirmation of a Δswi4::hisG/SWI4-3HA-URA3 strain. 
(A, B) Map and gel of a PCR screen to confirm intergration of a 3HA-URA3-containing construct 
at the C-terminus of SWI4. Oligonucleotides SWI4SF1 and SWI4SR1 amplify a 1264 bp band 
for SWI4-3HA (A). Positive strain VC300 (Δswi4::hisG/SWI4-3HA-URA3) and negative control 
strain BWP17 shown in (B). (C) Western blot containing 30 µg of whole cell protein extracts 
from strains VC300, (Δswi4::hisG/SWI4-3HA-URA3), VC150 (Δswi4::hisG/SWI4-13MYC-HIS1, 











Figure 13. Confirmation of a MBP1-13MYC-HIS1/MBP1 strain. 
(A, B) Map and gel of a PCR screen to confirm intergration of a 13MYC-HIS1-containing 
construct at the C-terminus of MBP1. Oligonucleotides CaHIS1F and YC15R amplify a 970 bp 
band for MBP1-13MYC (A). Positive strains VC303, VC304 (MBP1-13MYC-HI1S/MBP1) and 
negative control strain BWP17 shown in (B). (C) Western blot containing 30 µg of whole cell 
protein extracts from strains VC303, VC304, VC308 (MBP1-13MYC-HIS1/MBP1), VC150 
(Δswi4::hisG/SWI4-13MYC-HIS1, MBP1/MBP1-3HA-ARG4), VC108 (Δswi4::hisG/SWI4-














Figure 14. Confirmation of a MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3 
strain. 
(A, B) Map and gel of a PCR screen to confirm intergration of a 13MYC-HIS1-containing 
construct at the C-terminus of MBP1. Oligonucleotides CaHIS1F and YC15R amplify a 970 bp 
band for MBP1-13MYC (A). Positive strains VC324, VC325, VC326 (MBP1-13MYC-
HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3) and negative control strain BWP17 shown in (B). 
(C) Western blot containing 30 µg of whole cell protein extracts from strains VC324, VC325, 
VC326 (MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3), VC150 














Figure 15. Co-immunoprecipitation demonstrates a possible interaction between Swi4p and 
Mbp1p when Swi4p is immune-precipitated, but not when Mbp1p is pulled down. 
Western blot of whole cell extract and immune-precipitates from strains VC304 (MBP1-13MYC-
HIS1/MBP1), VC324 (MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3), and VC300 
(Δswi4::hisG/SWI4-3HA-URA3) using anti-HA agaorose (A) or anti-MYC agarose (B). A signal 
is observed in the control strain (A) but is less intense than that observed in the experimental 
strain. 40 µl of beads were incubated with 40 mg of protein overnight, washed, and boiled in 












Figure 16. Co-immunoprecipitation demonstrates that Swi4p and Mbp1p do not interact 
when the amount of input protein is reduced. 
Western blot of whole cell extract and immune-precipitates from strains VC304 (MBP1-13MYC-
HIS1/MBP1), VC324 (MBP1-13MYC-HIS1/MBP1, Δswi4::hisG/SWI4-3HA-URA3), and VC300 
(Δswi4::hisG/SWI4-3HA-URA3) using anti-HA agarose (A) or anti-MYC agarose (B). 20 µl of 
beads were incubated with 2 mg of protein overnight, washed, and boiled in SDS sample buffer 











Figure 17. Construction of a strain carrying CDC5-3HA in a SWI6-TAP-URA3/SWI6, 
Δcln3::hisG/MET::CLN3-ARG4 background. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-HIS1-containing 
construct at the C-terminus of CDC5. Oligonucleotides CaHIS1F and AG2R produced a 1035 bp 
band for CDC5-3HA. Positive strains VC181, VC183 (CDC5-3HA-HIS1/CDC5, SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) and negative control strain BWP17 shown in (B). 
(C) Western blot containing 30 µg of whole cell protein extracts from strains VC181, VC183, 
VC188, (CDC5-3HA-HIS1/CDC5, SWI6-TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4), 











Figure 18. Confirmation of tagging CDC5 with HA in BH253 (Δcln3::hisG/MET::CLN3-
ARG4). 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-HIS1-containing 
construct at the C-terminus of CDC5. Oligonucleotides CaHIS1F and AG2R produced a 1035 bp 
band for CDC5-3HA. Positive strains VC380 (CDC5-3HA-HIS1/CDC5, 
Δcln3::hisG/MET::CLN3-ARG4) and negative control strain BWP17 shown in (B). (C) Western 
blot containing 30 µg of whole cell protein extracts from strains VC378, VC380 (CDC5-3HA-
HIS1/CDC5, Δcln3::hisG/MET::CLN3-ARG4), VC150 (Δswi4::hisG/SWI4-13MYC-HIS1, 













Figure 19. Co-immunoprecipitation demonstrating an interaction between Cdc5p and 
Swi6p in G1 phase-blocked cells when Cdc5p-HA is immune-precipitated. 
Western blot of whole cell extract and immune-precipitates from strains YC221 (SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4), VC181 (CDC5-3HA-HIS1/CDC5, SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4), and VC380 (CDC5-3HA-HIS1/CDC5, 
Δcln3::hisG/MET::CLN3-ARG4) grown in repressing medium (+MC) for 4 h to induce a G1-
phase block, using anti-HA agaorose (A) or anti-TAP agarose (B). Proteins were not incubated 
with anti-TAP antibody in part B due to non-specific cross reaction already seen in control lane 
when pulled out with IgG beads. 40 µl of beads were incubated with 40 mg of protein for 4 














Figure 20. Co-immunoprecipitation does not support an interaction between Cdc5p and 
Swi6p in exponential growing cells as opposed to G1 phase blocked cells, due to strong non-
specific cross reaction. 
Western blot of whole cell extract and immune-precipitates from strains YC221 (SWI6-TAP-
URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) and VC181 (CDC5-3HA-HIS1/CDC5, SWI6-
TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4) using anti-HA agaorose. 40 µl of beads were 
incubated with 40 mg of protein overnight, washed, and boiled in SDS sample buffer to elute 
















Figure 21. Confirmation of a SWI6-3HA-URA3/SWI6, CDC5-13MYC-HIS1/CDC5 strain. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a 3HA-URA3-containing 
construct at the C-terminus of SWI6. Oligonucleotides CaURA3F and SWI6SR1 produced an 
898 bp band for SWI6-3HA. Positive strain VC348 (SWI6-3HA-URA3/SWI6, CDC5-13MYC-
HIS1/CDC5) and negative control strain BWP17 shown in (B). (C) Western blot containing 30 
µg of whole cell protein extracts from strains VC348, VC351, VC352 (SWI6-3HA-URA3/SWI6, 
CDC5-13MYC-HIS1/CDC5), VC150 (Δswi4::hisG/SWI4-13MYC-HIS1, MBP1-3HA-














Figure 22. Co-immunoprecipitation demonstrates a possible interaction between Cdc5p 
and Swi6p when Swi6p-HA is immune-precipitated from exponential-growing cells, but not 
when Cdc5p-MYC is pulled down. 
Western blots of whole cell extracts and immune-precipitates from strains AG625 (CDC5-
13MYC-HIS1/CDC5), VC348 (SWI6-3HA-URA3/SWI6, CDC5-13MYC-HIS1/CDC5), and 
YC211 (Δswi6::HIS1/SWI6-3HA-URA3), using anti-HA agarose (A) or anti-MYC beads (B). 
Proteins were not incubated with anti-TAP antibody in part B due to non-specific cross reaction 
already seen in control lane when pulled out with IgG beads. 40 mg of protein was incubated 
with 40 µl of beads overnight, washed, and were boiled in SDS sample buffer for the elution of 













Figure 23. Confirmation of a SWI6-3HA-URA/SWI6, Δcdc5::hisG/MET3::CDC5-ARG4 
strain. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-URA3-containing 
construct at the C-terminus of SWI6. Oligonucleotides CaURA3F and SWI6SR1 produced an 
898 bp band for SWI6-3HA. Positive strains VC426, VC427 (SWI6-3HA-URA3/SWI6, 
Δcdc5::hisG/MET::CDC5-ARG4), YC216 (Δswi6::hisG/SWI6-3HA-URA3) and negative control 
strain BWP17 shown in (B). (C) Western blot containing 30 µg of whole cell protein extracts 
from strains VC426, VC427 (SWI6-3HA-URA3/SWI6, Δcdc5::hisG/MET::CDC5-ARG4), VC181 
(CDC5-3HA-HIS1/CDC5, SWI6-TAP-URA3/SWI6, Δcln3::hisG/MET::CLN3-ARG4), and 











Figure 24. Swi6p is not modulated over time upon depletion of Cdc5p. 
Western blot of strains VC426 (SWI6-3HA-URA3/SWI6, Δcdc5::hisG/MET::CDC5-ARG4) and 
YC216 (Δswi6::HIS1/SWI6-3HA-URA3) that were incubated in +MC repressing or –MC 
inducing medium for the indicated times.  Blots were incubated with anti-HA antibody to 




















Figure 25. Confirmation of a RPN1-3HA-URA3/RPN1, Δswi4::hisG/SWI4-13MYC-HIS1 
strain. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-URA3-containing 
construct at the C-terminus of RPN1. Oligonucleotides CaURA3F and VC9R produced an 892 
bp band for RPN1-3HA. Positive strains VC389, VC390 (RPN1-3HA-URA3/RPN1, 
Δswi4::hisG/SWI4-13MYC-HIS1), and negative control strain BWP17 shown in (B). (C) 
Western blot containing 30 µg of whole cell protein extracts from strains VC389, VC390, 
VC391 (RPN1-3HA-URA3/RPN1, Δswi4::hisG/SWI4-13MYC-HIS1), VC348 (SWI6-3HA-













Figure 26. Confirmation of a RPN1-3HA-URA3/RPN1 strain. 
(A, B) Map and DNA gel of a PCR screen to confirm intergration of a  3HA-URA3-containing 
construct at the C-terminus of RPN1. Oligonucleotides CaURA3F and VC9R produced an 892 
bp band for RPN1-3HA. Positive strain VC394 (RPN1-3HA-URA3/RPN1), and negative control 
strain BWP17 shown in (B). (C) Western blot containing 30 µg of whole cell protein extracts 
from strains VC394 (RPN1-3HA-URA3/RPN1), VC389 (RPN1-3HA-URA3/RPN1, 
Δswi4::hisG/SWI4-13MYC-HIS1), VC348 (SWI6-3HA-URA3/SWI6, CDC5-13MYC-
















       
           
Figure 27. Northern blot showing EFG1 expression in the presence or absence of SWI4, 
SWI6, or MBP1. 
RNA was extracted from swi4 Δ/Δ, swi6 Δ/Δ, and mbp1 Δ/Δ mutant strains and their respective 
complement strains in addition to control strain, to analyze EFG1 expression patterns. 
Expression of EFG1 is slightly decreased in swi6 Δ/Δ mutant cells compared to SWI6 containing 
cells. Expression of EFG1 is slightly decreased in swi4 Δ/Δ mutant cells (part A). Next, RNA 
extracted from cells under SWI4 repressing conditions was analyzed for EFG1 expression 
patterns at different time points in the presence and absence of SWI4. EFG1 is moderately 







Figure 28. Construction of strain lacking EFG1 in a swi4 Δ/Δ mutant background. PCR 
screens confirming swi4/efg1 double mutant strains. 
(A, B) Map and PCR screening gel of the deletion of first allele of EFG1, showing a 1199 bp 
band for Δefgl::ARG4 (A) and second EFG1 allele, showing a 1356 bp band for Δefgl::HIS1 (B). 
(C) Map and PCR screening results for confirming the deletion of both EFG1 alleles, showing 




swi4/swi4, efg1/efg1  
 




               
Figure 29. Influence of the absence of Efg1p on the swi4/swi4 phenotype. 
Strains VC166 (Δefg1::ARG4/EFG1, Δswi4::hisG/Δswi4::URA3) and VC247 (Δefg1::ARG4/ 





















Table 4. Selected Swi6p-enriched targets1 
Protein ID 
Number of 
peptides ORF Name 
Present in 
control Protein Description 
CAL0005042 4 CDC5/orf19.6010 N Verified ORF; Polo-like kinase; 
member of conserved Mcm1 regulon; 
depletion causes defects in spindle 
elongation and Cdc35-dependent 
filamentation; virulence-group-
correlated expression; likely essential 
(UAU1 method); Spider biofilm 
repressed 
CAL0001395 7 orf19.5722 N Uncharacterized ORF; Has domain(s) 
with predicted DNA binding activity 
and role in regulation of transcription; 
DNA-dependent 
1Complete list of Swi6p-enriched targets can be accessed from paper ‘Characterization of putative G1/S 
transcription complex factors Swi6p, Swi4p and Mbp1p in the fungal pathogen Candida albicans’ by Chen, Y 
(2013). 
 
Table 5. Selected Swi4p-enriched targets1 
1Complete list of Swi4p-enriched targets can be accessed from paper ‘Characterization of putative G1/S 
transcription complex factors Swi6p, Swi4p and Mbp1p in the fungal pathogen Candida albicans’ by Chen, Y 
(2013).                                           
 
  






CAL0006334 10 RPN1/orf19.4956 N Uncharacterized ORF; Putative 19S 
regulatory particle of the 26S 
proteasome; regulated by Gcn2p and 
Gcn4p 
CAL0001433 6 RPN3/orf19.3054 N Uncharacterized ORF; Putative non-
ATPase regulatory subunit of the 26S 
proteasome lid; amphotericin B 
repressed; oxidative stress-induced via 
Cap1p 
CAL0006022 10 RPT6/orf19.3593 N Uncharacterized ORF; Putative 
ATPase of the 19S regulatory particle 
of the 26S proteasome; transcript 
regulated by Mig1; regulated by Gcn2 
and Gcn4 
CAL0001552 9 PR26/orf19.5793 N Uncharacterized ORF; Protein with 
similarity to proteasomal 26S 








A comprehensive understanding of the regulation of the G1/S transition in C.albicans has 
important implications for identifying factors that are important for cell proliferation and 
morphogenesis, both of which are important for virulence. Based on genetic and DNA 
expression data, previous reports suggested that C. albicans contained a single MBF-like G1/S 
transcription complex consisting of the major components Swi4p and Swi6p [42, 48, 49], 
although biochemical data supporting this interaction was lacking. However, additional factors 
were proposed to contribute to G1/S control in C. albicans, based on the fact that C. albicans 
cells lacking Swi6p and Swi4p or Swi4p and Mbp1p, were still viable [48]. Subsequent work 
from Y. Chen in the Bachewich lab demonstrated that Swi4p and Swi6p physically interact to 
form a complex, in support of the model based on affinity purification and co-
immunoprecipitation experiments. However, the latter used a high amount of input protein.   
Mbp1p also interacted with Swi6p, and experiments to test for an interaction between Swi4p and 
Mbp1p were inconclusive, questioning the composition and number of complexes governing the 
G1/S transition. Further, systematic affinity purification of Swi6p, Swi4p and Mbp1p revealed 
additional putative interacting proteins. However, these interactions were not validated using 
other approaches.  Finally, ChIP-chip analysis identified putative Swi4p targets involved in G1/S 
control, as predicted, but also in hyphal development, including the core hyphal regulator Efg1p.  
However, the functional significance of this occupation was not further explored.   
In addressing these outstanding issues, we obtained results that confirm that Swi6p 
interacts with Swi4p but also Mbp1p. However, only a weak interaction between Swi4p and 
Mbp1p could be detected when Swi4p, but not Mbp1p, was pulled down, suggesting that C. 
albicans contains a Swi6p/Swi4p complex as well as a Swi6p/Mbp1p complex. Since the latter 
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does not appear to be important in G1/S control in yeast under standard growth conditions [65], 
its function thus remains unclear. The results also confirm an interaction between Swi6p and the 
mitotic polo kinase Cdc5p, which has not been reported in other systems. Finally, we also 
provide evidence that supports a functional link between Swi4p and the promoter of the core 
hyphal regulator Efg1p.  
4.1 C. albicans Swi6p binds Swi4p and Mbp1p but in separate complexes  
Although C. albicans contains homologues of Swi6p, Swi4p and Mbp1p, a single 
complex consisting of Swi6p and Swi4p was proposed to function in G1/S regulation, as absence 
of Mbp1p did not strongly affect yeast growth, unlike absence of Swi4p or Swi6p [48, 49], and 
promoters of G1/S-associated genes were enriched for an MBF motif [42]. However, our finding 
that Swi6p binds Swi4p and Mbp1p, even with reduced amounts of input protein in co-
immunoprecipitation experiments, suggests that separate Swi4p/Swi6p and Swi6p/Mbp1p 
complexes exist in C. albicans. If all three proteins existed in a single complex, we predict that 
affinity purification of Swi4p or Mbp1p should reveal co-precipitation of the Mbp1p or Swi4p, 
respectively. However, affinity purification of these factors followed by mass spectrometry did 
not reveal binding. When tested further with co-immunoprecipitation, binding was detected only 
when Swi4p was pulled down with high amounts of input protein (40mg). This demonstrates 
that, if an interaction exists, it is not of the same strength as that observed between Swi6p and 
Swi4p or Swi6p and Mbp1p. We cannot rule out that this is due to an indirect interaction 
between Swi4p and Mbp1p through Swi6p, and that the three proteins may be present in a single 
complex. However, the fact that Mbp1p has little effect on yeast growth yet is a dominant 
interacting factor of Swi6p implies that a separate Swi6p/Mbp1p complex is present in C. 
albicans. The function of this, however, remains obscure. Possibilities include functions under 
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different growth conditions or in different cell types. Consistent with this, Res2p from the MBF 
complex in S. pombe has a more dominant function during meiosis compared to mitotic growth 
[18]. Intriguingly, the filamentous fungus Aspergillus nidulans has single sequence homologues 
of SWI6 and MBP1, yet absence of both has little effect on vegetative growth [66]. Thus, there is 
precedence for divergence in G1/S regulation in fungi. Future experiments are aimed at 
determining the function of Mbp1p through ChIP-chip, gel-shift assays, and determining 
phenotype of the mbp1/mbp1 strain, expression of MBP1 and Mbp1p, and post-translational 
modifications of Mbp1p, under diverse growth conditions and in different cell types including 
the opaque cell form.  
4.2 Swi6p interacts with polo-like kinase Cdc5p: a novel interaction 
A putative interaction between Swi6p and the polo-like kinase Cdc5p was suggested by 
previous experiments involving affinity purification followed by mass spectrometry. We have 
now confirmed the interaction using co-immunoprecipitation. We were not able to detect a 
strong interaction in exponential phase vs. G1-blocked cells, agreeing with previous affinity 
purification/mass spectrometry data and raising the possibility that this interaction is specific or 
enhanced in G1 phase. This interaction has not been reported in other systems and is thus novel.  
However, the functional significance remains unclear. Cdc5p belongs to the polo-like kinase 
family of serine/threonine kinases that are conserved from yeast to man [67]. While the major 
conserved functions lie in mitosis and cytokinesis, multi-cellular organisms contain additional 
homologues that function during G1 and S phase. Cdc5p in S. cerevisiae functions in regulating 
mitotic progression through the APC/C [68], FEAR network [69] and MEN pathway [70], as 
well as in septation via RhoA [71]. Cdc5p is cell-cycle regulated and expression of protein levels 
peak at the G2/M transition [72]. However, the protein is present in low levels and can be 
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detected at the spindle pole body as early as G1 phase [73, 74]. Further, Cdc5p has a role in 
spindle pole body maturation [75].  In C. albicans, Cdc5p localizes to the spindle pole body and 
chromatin, even in unbudded, G1-phase cells [50], and Cdc5p is required for metaphase 
progression and spindle elongation [50]. However, it has not been extensively characterized at 
the biochemical level in a cell-cycle-dependent manner. Transcription profiles of Cdc5p-depleted 
cells indicated a global repression of histones, suggesting an S phase arrest, but FACS 
demonstrated that cells contained a 4n content of DNA [50]. However, CDC5 is upregulated at 
G2/M [42], prior to the time in the cell cycle when Swi6p is required. Thus, in one model to 
explain our results, Cdc5p may influence Swi6p function in early G1 phase through 
phoshorylation. In order to test this, we analyzed Swi6p mobility during a time course of Cdc5p 
repression. No significant difference was observed, but a decrease in Swi6p abundance was 
noted. This was not quantified, so we cannot rule out differences in loading. However, if real, the 
result suggests that Cdc5p may influence the stability of Swi6p. Little is currently known about 
the regulation of Swi6p in C. albicans, but more insights on the relevance of an interaction 
between Swi6p and Cdc5p may be gleaned by repeating the experiments with a more refined 
time course, synchronized cells, and under different growth conditions. In S. cerevisiae, Swi6p is 
shuttled between nucleus and cytoplasm as a means of regulation. To determine whether Cdc5p 
might influence Swi6p translocation in C. albicans, localization in living cells under conditions 
of Cdc5p depletion could be employed. Another model could involve indirect interactions 
through a common intermediate. Cdc5p and other Plks have been located at gene promoters 
through interactions with transcription factors [76], including Plo1p from S. pombe, which is 
required for regulating expression of genes at the M/G1 transition [77].   
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Another Swi6p interacting factor identified through previous affinity purification and 
mass spectrometry analysis included a hypothetical protein, orf19.5722p that has a DNA-binding 
domain. The orthologue in S. cerevisiae is NSI1, which is an RNA polymerase I termination 
factor and involved in ribosomal RNA transcription [78]. Since orf19.5722p has putative DNA-
binding ability and may bind Swi6p, it is possible that it contributes to the G1/S transition. 
Oligonucleotides were designed to tag this protein for co-immunoprecipitation experiments to 
confirm an interaction with Swi6p, but this work was not yet completed.  
4.3 Swi4p putative interactions with components of the proteasome: implications for 
regulation 
In S. cerevisiae, SWI4 expression is periodic and peaks during G1 phase, while Swi4p is 
present throughout the cell cycle and remains in the nucleus [79]. Its regulation has not been 
linked to cell-cycle-dependent, targeted degradation. In contrast, previous work from our lab 
demonstrated through affinity purification and mass spectrometry that Swi4p in C. albicans may 
bind several components of the 26S proteasome and the 19S regulatory subunit, including Pr26p, 
Rpn1p, Rpn3p, and Rpt6p. The 26S proteasome is comprised of many subunits that consist of a 
proteolytic core complex (the 20S proteasome) and 19S regulatory complexes. They remove 
ubiquitin chains and transfer the target proteins into the proteolytic core for degradation [62].  
SWI4 in S. cerevisiae shows genetic interactions with some RPN subunits [80-85] but no 
physical interactions have been reported. This has interesting implications for differential 
regulation of Swi4p and thus the G1/S transition in C. albicans. SWI4 levels peak at the G1/S 
transition [42], but little is known about specific forms of regulation. Future work will involve 
determining Swi4p levels during normal cell cycle progression in synchronized cells to 
determine if the protein is modulated at the level of stability, and confirming putative 
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interactions between Swi4p and proteasome subunits using co-immunoprecipitation. With 
respect to the latter, I completed construction of strains and investigations will be carried out by 
a subsequent graduate student.  
4.4 Swi4p targets EFG1: possible link between G1/S transition and filamentous 
development. 
Another major finding from Y. Chen was the observation that Swi4p located at the 
promoter of EFG1, a core regulator of the hyphal development program [37, 63]. The notion that 
EFG1 may be a target of Swi4p was significant since filamentous growth was associated with 
swi4∆/∆ cells [48].  In an attempt to determine whether this location was functional, I determined 
the effect of deleting EFG1 on the Swi4p-depleted phenotype, and measured EFG1 levels in 
strains lacking Swi4p. First, I demonstrated that swi4∆/∆ cells were reduced in size and showed 
less filamentation in the absence vs. presence of Efg1p, suggesting that Efg1p contributed in part 
to the phenotype. In comparison, Efg1p is required for hyphal growth under most hyphal-
inducing conditions [21], and is a direct target of Protein Kinase A (PKA) [86, 87]. I then 
demonstrated that EFG1 was moderately induced in response to absence of Swi4p, but this 
appeared to be a transient response since the change in expression was only noted during a 
period immediately following Swi4p depletion in the SWI4 conditional strain, and not in the 
swi4∆/∆ strain. This result suggests that Swi4p may have some repressive effect on EFG1 
expression under normal yeast growth conditions. Efg1p is a complex regulator as it is required 
for many processes in C. albicans, including the white phase yeast cell type [37, 38], biofilm 
formation [36], hyphal growth [21], adhesion and cell wall gene regulation [88], for example, 
and has both activating [39] and repressing activity [63]. EFG1 is expressed in yeast cells, but 
repressed quickly after yeast are exposed to hyphal-inducing conditions such as serum or Lee’s 
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medium, although expression levels eventually recover [63, 89]. This is due to the fact that 
Efg1p shows negative autoregulation [89]. Thus, with respect to hyphae development, Efg1p is 
required within a window immediately after hyphal induction to help down-regulate the 
repressor NRG1, negatively autoregulate itself, and control other genes [64]. Efg1p is suggested 
to have a negative effect on maintenance of hyphal growth, consistent with its down-regulation 
after hyphal induction [63, 64, 89]. Notably, overexpression of Efg1p can drive filamentous 
growth in the form of pseudohyphae [63].  
With respect to our results, it is thus possible that under yeast growth conditions, Swi4p 
alone or in combination with other proteins has a repressive effect on EFG1 that maintains 
expression at a specific level. Absence of Swi4p results in moderate induction of EFG1, and this 
may contribute to the phenotype, which includes filamentous growth. Given that cells depleted 
of Swi4p grew in a filamentous form and expressed some hyphal-specific genes [48], this result 
could provide a mechanism that links Swi4p function to development. However, it is important 
to note that the swi4∆/∆ cells are pleiotropic and not all filaments are true hyphae. Further, cells 
in the yeast form were significantly enlarged, which we suggested was due to a delay in G1 
phase [48]. Combined with the fact that Efg1p has multiple functions [21], we thus can’t rule out 
the possibility that Swi4p occupation of the EFG1 promoter is important for other processes.  
Intriguingly, the swi4∆/∆ cells lacking Efg1p were also reduced in size, suggesting some 
suppression of the G1/S delay. Efg1p was previously shown to be capable of binding MCB sites 
in one hybrid and gel-retardation assays, but not in in vivo ChIP-chip studies [64, 90]. Thus, Efg1 
is a target of Swi4p, but the functional significance of this occupation requires further 
investigation. Future experiments will include analysis of the EFG1 promoter for the region 
binding Swi4p, cloning that region to a reporter to visualize EFG1 expression in the presence 
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and absence of Swi4p in vivo under different growth conditions and in various cell types, and 
time-course-based ChIP experiments to investigate the dynamics of Swi4p occupation of the 
EFG1 promoter.  
In summary, this work has provided more insights on the G1/S transcription factor 
complex in C. albicans, including composition and function. Importantly, it has also identified a 
possible mechanism by which Swi4p is linked to Efg1p, a critical regulator of many processes 
important for virulence in C. albicans. The results also raise interesting questions on the function 
of the Swi6p/Mbp1p complex, the regulation of Swi4p, and the role of novel interactors of 
Swi6p, which will be the focus of future investigations aimed at understanding the regulation of 
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